The study, Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor, has been published in Diabetes, Obesity and Metabolism. Researchers looked at the recently completed EMPA-REG study, which demonstrated that Empagliflozin significantly decreased major adverse cardiac events (MACE) in people with type 2 diabetes, deemed high risk.
